Current perspectives on CHEK2 mutations in breast cancer
- PMID: 28553140
- PMCID: PMC5439543
- DOI: 10.2147/BCTT.S111394
Current perspectives on CHEK2 mutations in breast cancer
Abstract
Checkpoint kinase 2 (CHEK2) is a serine/threonine kinase which is activated upon DNA damage and is implicated in pathways that govern DNA repair, cell cycle arrest or apoptosis in response to the initial damage. Loss of kinase function has been correlated with different types of cancer, mainly breast cancer. CHEK2 functionality is affected by different missense or deleterious mutations. CHEK2*1100delC and I157T are most studied in populations all over the world. Although these variants have been identified in patients with breast cancer, their frequency raises doubts about their importance as risk factors. The present article reviews the recent advances in research on CHEK2 mutations, focusing on breast cancer, based on the latest experimental data.
Keywords: CHEK2; breast cancer.
Conflict of interest statement
Disclosure The authors report no conflicts of interests in this work.
Figures
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
-
- Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. - PubMed
-
- Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(2):122–192. - PubMed
-
- Dufault MR, Betz B, Wappenschmidt B, et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer. 2004;110(3):320–325. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
